Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia

European Journal of Heart Failure
Piergiuseppe AgostoniPietro Palermo

Abstract

To evaluate whether carvedilol influences exercise hyperventilation and the ventilatory response to hypoxia in heart failure (HF). Fifteen HF patients participated to this double blind, randomised, placebo controlled, cross-over study. Patients were evaluated by quality of life questionnaire, echocardiography, pulmonary function and cardiopulmonary exercise tests (ramp and constant workload) both in normoxia (FiO2 = 21%) and hypoxia (FiO2 = 16%, equivalent to a simulated altitude of 2000 m). Carvedilol improved clinical condition and reduced left ventricle size, but had no effect on lung mechanics. In normoxia during exercise, ventilation was lower, V(CO2) unchanged and PaCO2 (constant workload) or PetCO2 (ramp) higher with carvedilol, exercise capacity was unchanged (peak workload 92+/-22 and 90+/-22W for placebo and carvedilol, respectively). Abnormal V(E)/V(CO2) slope was reduced by carvedilol. Hypoxia increased ventilation but less with carvedilol; exercise capacity decreased to 87+/-21W (placebo) and to 80+/-11 W (carvedilol, p < 0.01). With hypoxia, carvedilol decreased V(E)/V(CO2) slope. At constant workload exercise with hypoxia, PaO2 decreased to 69+/-6 mm Hg (placebo) and to 64+/-5 (carvedilol, p < 0.01). Carvedilol r...Continue Reading

References

Sep 1, 1975·Journal of Applied Physiology·K WassermanM G Cleary
Sep 1, 1992·American Heart Journal·J MyersV F Froelicher
Nov 1, 1990·Circulation·J Myers, V F Froelicher
Apr 19, 1986·British Medical Journal·D P Lipkin, P A Poole-Wilson
Jun 1, 1986·Journal of Applied Physiology·W L BeaverB J Whipp
Feb 1, 1993·Journal of the American College of Cardiology·P G AgostoniM D Guazzi
Mar 1, 1996·Journal of the American College of Cardiology·T P ChuaA J Coats
Jan 1, 1997·Journal of the American College of Cardiology·T P ChuaA J Coats
Jun 1, 1997·Journal of the American College of Cardiology·T P ChuaA J Coats
Jul 1, 1997·Journal of the American College of Cardiology·P A HeidenreichB M Massie
Oct 23, 1997·Circulation·K WassermanP G Agostoni
Mar 16, 2002·Journal of Applied Physiology·Piergiuseppe AgostoniVito Brusasco
Oct 23, 2002·Circulation·Milton PackerUNKNOWN Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group
Dec 9, 2003·Journal of Applied Physiology·Nanduri R Prabhakar, Ying-Jie Peng
Apr 20, 2004·Journal of Applied Physiology·H Thomas RobertsonPierGiuseppe Agostoni
Jun 1, 2005·European Journal of Heart Failure·Piergiuseppe AgostoniKarlman Wasserman

❮ Previous
Next ❯

Citations

Oct 1, 2009·Cardiovascular Drugs and Therapy·Piergiuseppe AgostoniMauro Contini
Jan 11, 2011·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Massimo F PiepoliUNKNOWN Working Group ‘Exercise Physiology, Sport Cardiology and Cardiac Rehabilitation’, Italian Society of Cardiology
Feb 1, 2013·Pulmonary Medicine·Anna ApostoloPiergiuseppe Agostoni
Jan 25, 2011·American Journal of Respiratory and Critical Care Medicine·Darryl Y Sue
Aug 8, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Akihiko TajimaKarlman Wasserman
Jun 15, 2013·Pulmonary Medicine·Roberta P RamosJ Alberto Neder
Aug 1, 2014·Journal of Cardiac Failure·Sofie PardaensJohan de Sutter
Sep 11, 2007·High Altitude Medicine & Biology·Martin FaulhaberMartin Burtscher
Oct 6, 2010·High Altitude Medicine & Biology·Christoph Dehnert, Peter Bärtsch
Jun 26, 2013·High Altitude Medicine & Biology·Piergiuseppe Agostoni
Apr 17, 2009·Canadian Journal of Physiology and Pharmacology·Karl WerdanUrsula Müller-Werdan
Jan 16, 2010·Expert Opinion on Drug Metabolism & Toxicology·Subhashis ChakrabortySanjay Singh
Jun 24, 2010·American Heart Journal·Piergiuseppe AgostoniMauro Contini
Apr 27, 2010·Progress in Cardiovascular Diseases·Stefano F RimoldiYves Allemann
Mar 3, 2007·Progress in Cardiovascular Diseases·Klaus K Witte, Andrew L Clark
Jun 15, 2007·European Journal of Heart Failure·Piergiuseppe AgostoniCesare Fiorentini
Jan 28, 2012·Cardiovascular Therapeutics·Dennis LadageKlara Brixius
Apr 1, 2011·European Journal of Preventive Cardiology·Marlus KarstenPiergiuseppe Agostoni
Apr 5, 2017·Annals of the American Thoracic Society·Mauro Contini
Jul 14, 2017·Journal of Hypertension·Laurent WinklerJean-Paul Richalet
Nov 7, 2007·Circulation·Peter Bärtsch, J Simon R Gibbs
Jun 11, 2018·Journal of the American Heart Association·Sergio CaravitaGianfranco Parati
Feb 5, 2021·European Respiratory Review : an Official Journal of the European Respiratory Society·Piergiuseppe AgostoniElisabetta Salvioni
Apr 29, 2021·Praxis·Jan Vontobel
Sep 10, 2021·Journal of the American Heart Association·William K CornwellUNKNOWN American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical C

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.